AstraZeneca has committed $50 billion over the next five years to manufacturing and R&D projects across the United States, including a new drug factory in Virginia, its largest to date. This investment aims to scale production of small molecules, peptides, and oligonucleotides, expanding capacity for metabolic and weight management drugs. CEO Pascal Soriot emphasized the US as a strategic innovation hub, with revenue targets reflecting increased US market share by 2030. The announcement comes as the industry faces potential pharmaceutical tariffs under the current administration.